NRF2 and cancer: the good, the bad and the importance of context
Open accessThe DOI matches its Crossref record; 119 of the 120 references it cites were found in a registry or an index.
Abstract
Many studies of chemopreventive drugs have suggested that their beneficial effects on suppression of carcinogenesis and many other chronic diseases are mediated through activation of the transcription factor NFE2-related factor 2 (NRF2). More recently, genetic analyses of human tumours have indicated that NRF2 may conversely be oncogenic and cause resistance to chemotherapy. It is therefore controversial whether the activation, or alternatively the inhibition, of NRF2 is a useful strategy for the prevention or treatment of cancer. This Opinion article aims to rationalize these conflicting perspectives by critiquing the context dependence of NRF2 functions and the experimental methods behind these conflicting data.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“NRF2 is mutationally activated in 10–30% of different solid tumors including liver, lung, stomach, colon and other cancers and mutations typically disrupt the interaction between NRF2 and its E3 ligase KEAP1 (Kelch Like ECH Associated Protein 1) directly or by impeding KEAP1 co-factors CUL3 (Cullin 3) and CAND1 (Cullin Associated and Neddylation Dissociated 1) [2,5,6,7,8].”
From NRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy (2021) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“NRF2 is activated and overexpressed in cancer to promote cancer cell survival; the cellular antioxidant system is largely regulated by NRF2 and its associated genes.30”
From Reactive Oxygen Species in Cancer: Current Findings and Future Directions (2021) · cites this paper as [30]
In the citing paper
“Furthermore, increased ROS levels facilitate the activation of HIF1α and NRF2 transcription factors, thus promoting transcriptional programs that further contribute to tumorigenesis (Bertout et al., 2008; Sporn and Liby, 2012).”
From The emerging hallmarks of cancer metabolism (2016) · cites this paper as Sporn and Liby, 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
3 retracted
Niture, S. K., Jain, A. K., & Jaiswal, A. K. (2009) · Journal of Cell Science · doi:10.1242/jcs.058537 · Cited by 192
RetractedPhosphorylation and Dephosphorylation of Tyrosine 141 Regulate Stability and Degradation of INrf2
Jain, A. K., Mahajan, S., & Jaiswal, A. K. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m709854200 · Cited by 49
RetractedHsp90 Interaction with INrf2(Keap1) Mediates Stress-induced Nrf2 Activation
Niture, S. K., & Jaiswal, A. K. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.175802 · Cited by 41
RetractedTargeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?
Trachootham, D., Alexandre, J., & Huang, P. (2009) · Nature Reviews Drug Discovery · doi:10.1038/nrd2803 · Cited by 5,452
Itoh, K., Chiba, T., Takahashi, S., Ishii, T., Igarashi, K., Katoh, Y., Oyake, T., Hayashi, N., Satoh, K., Hatayama, I., et al. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6943 · Cited by 3,999
The Consensus Coding Sequences of Human Breast and Colorectal Cancers
Sjöblom, T., Jones, S., Wood, L. D., Parsons, D. W., Lin, J., Barber, T. D., Mandelker, D., Leary, R. J., Ptak, J., Silliman, N., et al. (2006) · Science · doi:10.1126/science.1133427 · Cited by 3,169
Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Protein tyrosine phosphatases: from genes, to function, to disease
Tonks, N. K. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2039 · Cited by 1,677
Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer
Siegel, P. M., & Massagué, J. (2003) · Nature Reviews Cancer · doi:10.1038/nrc1208 · Cited by 1,604
Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution
Taguchi, K., Motohashi, H., & Yamamoto, M. (2011) · Genes to Cells · doi:10.1111/j.1365-2443.2010.01473.x · Cited by 1,478
Cited by
Items 501–600 of 1,000
Binding of disordered proteins to a protein hub
Cino, E. A., Killoran, R. C., Karttunen, M., & Choy, W. (2013) · Scientific Reports · doi:10.1038/srep02305 · Cited by 41
Resveratrol Suppresses PAI-1 Gene Expression in a HumanIn VitroModel of Inflamed Adipose Tissue
Zagotta, I., Dimova, E. Y., Funcke, J., Wabitsch, M., Kietzmann, T., & Fischer‐Posovszky, P. (2013) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2013/793525 · Cited by 35
“The NFE2-related factor 2 (Nrf2) is a key transcription factor, involved in the primary cellular defense against the cytotoxic effects of oxidative stress [62].”
BackgroundFavero, G. D., Zaharescu, R., & Marko, D. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2317-6 · Cited by 34
Alkaloids as Natural NRF2 Inhibitors: Chemoprevention and Cytotoxic Action in Cancer
Ackova, D. G., Maksimova, V., Smilkov, K., Buttari, B., Arese, M., & Saso, L. (2023) · Pharmaceuticals · doi:10.3390/ph16060850 · Cited by 39
“While NRF2 defends normal cells from oxidative stress, the excess of NRF2 in cancer cells may help them in adjusting to oxidative stress, surviving and resisting the redox environment (redox adaptation) [40,41].”
BackgroundThe mechanistic insights of the antioxidant Keap1-Nrf2 pathway in oncogenesis: a deadly scenario
Mukherjee, A. G., & Gopalakrishnan, A. V. (2023) · Medical Oncology · doi:10.1007/s12032-023-02124-4 · Cited by 38
Moreira, A. J., Rodrigues, G., Bona, S., Cerski, C. T. S., Marroni, C. A., Mauriz, J. L., González‐Gallego, J., & Marroni, N. P. (2014) · Toxicology Reports · doi:10.1016/j.toxrep.2014.11.015 · Cited by 33
Suppression of NRF2/ARE by convallatoxin sensitises A549 cells to 5-FU-mediated apoptosis
Lee, J., Kang, J.-S., Nam, L. B., Yoo, O.-K., & Keum, Y. (2018) · Free Radical Research · doi:10.1080/10715762.2018.1489132 · Cited by 35
“Introduction NF-E2-related factor 2 (NRF2) regulates the antioxidant response element (ARE)-dependent phase II cytoprotective genes [1] and contributes to the maintenance of homeostasis in response to oxidative stress [2].”
BackgroundImportance of the Keap1-Nrf2 pathway in NSCLC: Is it a possible biomarker? (Review)
Rodríguez, R. B. (2018) · Biomedical Reports · doi:10.3892/br.2018.1143 · Cited by 42
Nie, W., Zhou, K., Wang, Y., Wang, Z., Xie, Y., Zhou, H. M., & Xu, B. (2020) · Food & Function · doi:10.1039/d0fo02329a · Cited by 31
Majhi, S., Kumar, S., & Singh, L. (2022) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527321666220428134802 · Cited by 41
Chen, H.-H., Wang, T., Lee, Y.-C., Shen, P.-T., Chang, J., Yeh, T., Huang, C.-H., Chang, H.-H., Cheng, S.-Y., Lin, C., et al. (2015) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.5b00085 · Cited by 36
Batista, L., Gruosso, T., & Mechta‐Grigoriou, F. (2013) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2013.03.001 · Cited by 39
The Antinociceptive Role of Nrf2 in Neuropathic Pain: From Mechanisms to Clinical Perspectives
Petrikonis, K., Bernatonienė, J., Kopustinskienė, D. M., Casale, R., Davinelli, S., & Saso, L. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16081068 · Cited by 39
“On the other hand, excessive Nrf2 activity, often due to genetic mutations or cancerous alterations, can lead to an abnormal resistance against cellular apoptosis, aiding the survival of malignant cells [32,37].”
BackgroundKowalik, M. A., Sulas, P., Ledda‐Columbano, G. M., Giordano, S., Columbano, A., & Perra, A. (2015) · Oncotarget · doi:10.18632/oncotarget.5501 · Cited by 31
“Although the mechanisms responsible for the alternative fate of preneoplastic nodules are unknown, it is interesting to note that many of the genes found up-regulated in both EPFs and CK-19-positive nodules are targets of Nrf 2, a transcriptional factor that upon nuclear translocation induces the expression of genes i…”
Shimizu, T., Inoue, K.-I., Hachiya, H., Shibuya, N., Aoki, T., & Kubota, K. (2016) · Journal of Hepato-Biliary-Pancreatic Sciences · doi:10.1002/jhbp.364 · Cited by 33
Gu, C., Ramos, J., Begley, U., Dedon, P. C., Fu, D., & Begley, T. J. (2018) · Science Advances · doi:10.1126/sciadv.aas9184 · Cited by 32
Parthenolide and DMAPT induce cell death in primitive CML cells through reactive oxygen species
Flores-López, G., Moreno-Lorenzana, D., Ayala‐Sánchez, M., Avilés‐Vázquez, S., Torres‐Martinez, H., Crooks, P. A., Guzmán, M. L., Mayani, H., & Chávez‐González, A. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13755 · Cited by 33
Redox sensitive miR-27a/b/Nrf2 signaling in Cr(VI)-induced carcinogenesis
Wang, L., Bayanbold, K., Zhao, L., Wang, Y., Adamcakova‐Dodd, A., Thorne, P. S., Yang, H., Jiang, B., & Liu, L.-Z. (2021) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2021.151118 · Cited by 33
Reassessing the role of phytochemicals in cancer chemoprevention
Russo, G. L., Spagnuolo, C., & Russo, M. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116165 · Cited by 37
Thakur, S., Dhiman, M., & Mantha, A. K. (2017) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-017-3186-7 · Cited by 31
Shi, X., Liu, H., Li, S., & Xu, H. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.04.208 · Cited by 31
Sequestosome 1/p62-related pathways as therapeutic targets in hepatocellular carcinoma
Denk, H., Stumptner, C., Abuja, P. M., & Zatloukal, K. (2019) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2019.1601703 · Cited by 34
“tions of the Keap1/Nrf2 pathway are associated with early stages of the carcinogenic process, as shown in animal models [61,91,112].”
BackgroundAntioncogenic and Oncogenic Properties of Nrf2 in Arsenic-induced Carcinogenesis
Son, Y., Pratheeshkumar, P., Roy, R. V., Hitron, J. A., Wang, L., Divya, S. P., Xu, M., Luo, J., Chen, G., Zhang, Z., et al. (2015) · Journal of Biological Chemistry · doi:10.1074/jbc.m115.675371 · Cited by 31
“It has been shown that inducible Nrf2 activation is important in the anticancer effects of many natural compounds, including phenethyl isothiocyanate, curcumin, and resveratrol (12).”
BackgroundRetractedNandi, A., & Chowdhuri, D. K. (2020) · Journal of Hazardous Materials · doi:10.1016/j.jhazmat.2020.123737 · Cited by 30
Qin, Z., Ou, S., Xu, L., Sorensen, K., Zhang, Y., Hu, D., Yang, Z., Hu, W., Chen, F., & Prins, G. S. (2021) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13826 · Cited by 32
“Active Nrf2 signaling is a well-recognized chemoprevention event at the tumor-initiating stage; however, its powerful cytoprotective effects could be utilized by cancer cells to enforce survival, proliferation, metastasis, and treatment resistance (Rojo de la Vega et al., 2018; Sporn & Liby, 2012).”
BackgroundMori fructus aqueous extracts attenuates liver injury by inhibiting ferroptosis via the Nrf2 pathway
Wei, Y., Gao, C., Wang, H., Zhang, Y., Gu, J., Zhang, X., Gong, X.-H., & Hao, Z. (2023) · Journal of Animal Science and Biotechnology/Journal of animal science and biotechnology · doi:10.1186/s40104-023-00845-0 · Cited by 34
“Nrf2 is the central player in the regulation of antioxidant molecules [36] and is critical in mitigating lipid peroxidation and ferroptosis [37].”
BackgroundZhang, B., Zhao, J., Li, S., Zeng, L., Chen, Y., & Fang, J. (2015) · Pharmaceutical Biology · doi:10.3109/13880209.2014.927890 · Cited by 29
“Just as Nrf2 protects normal cells, studies have shown that Nrf2 may also protect cancer cells from chemotherapeutic agents and facilitate cancer progression (Jaramillo & Zhang, 2013; Sporn & Liby, 2012).”
BackgroundNRF2 Activation Confers Resistance to eIF4A Inhibitors in Cancer Therapy
Sanghvi, V. R., Mohan, P., Singh, K., Cao, L., Berishaj, M., Wolfe, A. L., Schatz, J. H., Lailler, N., de Stanchina, E., Viale, A., et al. (2021) · Cancers · doi:10.3390/cancers13040639 · Cited by 27
Nakamura, H., Takada, K., Arihara, Y., Hayasaka, N., Murase, K., Iyama, S., Kobune, M., Miyanishi, K., & Kato, J. (2019) · Cancer Gene Therapy · doi:10.1038/s41417-018-0056-8 · Cited by 29
Overexpression of NRF 2 is correlated with prognoses of patients with malignancies: A meta‐analysis
Guo, Y., & Shen, L. (2017) · Thoracic Cancer · doi:10.1111/1759-7714.12462 · Cited by 30
Nrf2-Keap1 in Cardiovascular Disease: Which Is the Cart and Which the Horse?
Dhyani, N., Tian, C., Gao, L., Rudebush, T., & Zucker, I. H. (2024) · Physiology · doi:10.1152/physiol.00015.2024 · Cited by 41
Expression of the Nrf2 and Keap1 proteins and their clinical significance in osteosarcoma
Zhang, J., Wang, X., Wu, W.-Z., Dang, H., & Wang, B. (2016) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2016.03.047 · Cited by 29
Expression of nuclear factor, erythroid 2-like 2-mediated genes differentiates tuberculosis
Qian, Z., Lv, J., Kelly, G. T., Wang, H., Zhang, X., Gu, W., Yin, X., Wang, T., & Zhou, T. (2016) · Tuberculosis · doi:10.1016/j.tube.2016.04.008 · Cited by 27
“negative regulator, which sequesters Nrf2 in the cytoplasm and directs it to CUL3 E3 ligase for unbiquitylation and subsequent degradation by the proteasome [2,3].”
BackgroundKruse, M., Friedrich, M., Arlt, A., Röcken, C., Egberts, J., Sebens, S., & Schäfer, H. (2016) · Inflammatory Bowel Diseases · doi:10.1097/mib.0000000000000925 · Cited by 29
Chen, N., Zhang, R., Konishi, T., & Wang, J. (2016) · Mutation Research/Genetic Toxicology and Environmental Mutagenesis · doi:10.1016/j.mrgentox.2016.11.006 · Cited by 31
“NRF2 (Nuclear Factor Erythroid 2-Related Factor 2), a member of the cap 'n collar family of basic leucine zipper transcription factors, plays central role in maintaining cellular oxidative equilibrium by transcriptionally activating detoxification enzymes such as heme oxyegenase-1 (HO-1) and NAD(P)H:quinone oxidoreduc…”
BackgroundAntineoplastic effects of auranofin in human pancreatic adenocarcinoma preclinical models
Perez, M. V. R., Roife, D., Dai, B., Pratt, M. F., Dobrowolski, R., Kang, Y., Li, X., Augustine, J. J., Zielinski, R. J., Priebe, W., et al. (2019) · Surgery Open Science · doi:10.1016/j.sopen.2019.05.004 · Cited by 30
The Nuclear Translocation of Heme Oxygenase-1 in Human Diseases
Yang, Q., & Wang, W. (2022) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2022.890186 · Cited by 32
“It frequently gathers in the nuclei of several malignant tumor cells as well as in the nucleus of oxidative stressmediated injury cells (Moi et al., 1994; Nguyen et al., 2009; Chen et al., 2012; Sporn and Liby 2012; Jaramillo and Zhang 2013; Shelton and Jaiswal 2013).”
BackgroundModulation of NRF2: Biological Dualism in Cancer, Targets and Possible Therapeutic Applications
Gallorini, M., Carradori, S., Panieri, E., Sova, M., & Saso, L. (2023) · Antioxidants and Redox Signaling · doi:10.1089/ars.2022.0213 · Cited by 33
Dong, D., Reece, E. A., & Yang, P. (2016) · Reproductive Sciences · doi:10.1177/1933719115625846 · Cited by 29
“Email: pyang@upi.umaryland.edu genes such as heme oxygenase 1 (HO-1), NAD(P)H quinine oxidoreductase 1 (NGC1), and glutamatecysteine ligase (GCL).37-39 A previous study has demonstrated that overexpression of Nrf2 dramatically inhibits hypertrophic factorinduced ROS production in both cardiomyocytes and cardiac fibrob…”
BackgroundHepatoblastoma modeling in mice places Nrf2 within a cancer field established by mutant β-catenin
Comerford, S. A., Hinnant, E. A., Chen, Y., Bansal, H., Klapproth, S., Rakheja, D., Finegold, M. J., Lopez-Terrada, D. H., O’Donnell, K. A., Tomlinson, G. E., et al. (2016) · JCI Insight · doi:10.1172/jci.insight.88549 · Cited by 31
Wang, J., SAUL, A. B., Cui, X., Roon, P., & Smith, S. B. (2017) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-21947 · Cited by 29
“56,57 In the absence of overt stress, NRF2 is retained in cytoplasm by KEAP1 (kelch-like ECH-associated protein 1).”
Friend or Foe? Mitochondria as a Pharmacological Target in Cancer Treatment
Dickerson, T., Jauregui, C. E., & Teng, Y. (2017) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0110 · Cited by 28
Vidović, T., & Ewald, C. Y. (2022) · Frontiers in Aging · doi:10.3389/fragi.2022.935220 · Cited by 33
“Nrf2 is considered both a tumor suppressor and oncogene regarding cancer (Sporn and Liby, 2012).”
BackgroundSun, Y., Li, Q., Huang, Y., Yang, Z., Li, G., Sun, X., Gu, X., Qiao, Y., Wu, Q., Xie, T., et al. (2024) · Chinese Medicine · doi:10.1186/s13020-024-00982-2 · Cited by 38
“High Nrf2 expression is associated with the resistance of several cancers to chemotherapy [173].”
BackgroundBiochemistry: A radical treatment
Garber, K. (2012) · Nature · doi:10.1038/489s4a · Cited by 31
Jiang, Z., Xu, L., Lu, M., Pan, Y., Huang, H., Zhang, X., Sun, H.-P., & You, Q. (2014) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-014-9799-y · Cited by 29
CDDO and Its Role in Chronic Diseases
Mathis, B. J., & Cui, T. (2016) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-41342-6_13 · Cited by 36
Chou, W., Hsu, C.-Y., Ho, C.-C., Hsieh, J., Chiang, H., Tsou, T., Chen, Y., & Lin, P. (2017) · Environmental Science & Technology · doi:10.1021/acs.est.7b02002 · Cited by 29
Xu, L., Liu, T., Wang, L., Li, L., Wu, Y., Li, C., Di, B., You, Q., & Jiang, Z. (2018) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2018/3271617 · Cited by 28
“The phosphorylation of the Nrf2 Ser40 by p-ERK promotes the transport of Nrf2 into the nucleus and its binding to ARE, leading to the coordinated expression of antioxidant proteins including NAD(P)H/quinone oxidoreductase 1 (NQO1), heme oxygenase-1 (HO-1), glutamate-cysteine ligase modifier subunit (GCLM), glutamate-c…”
BackgroundEstablishment of a SVM classifier to predict recurrence of ovarian cancer
Zhou, J., Li, L., Wang, L., Li, X., Xing, H., & Cheng, L. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9362 · Cited by 30
“Constitutive activation of nuclear factor erythroid 2 like 2 (NRF2) is associated with acquisition of malignant features in OC (28,29).”
BackgroundMiconazole Contributes to NRF2 Activation by Noncanonical P62-KEAP1 Pathway in Bladder Cancer Cells
Tsai, T., Chen, P., Lin, Y., Chou, K., Chen, H., Ho, C., Lin, J., & Hwang, T. I. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s227892 · Cited by 28
“KEAP1, an adaptor of the ubiquitin ligase complex that targets NRF2, plays a major role in NRF2 degradation.(12) When cells encounter oxidative stress or NRF2 activators, NRF2 quickly disassociates from KEAP1 and inhibits NRF2 degradation.”
BackgroundStuchi, L. P., Castanhole-Nunes, M. M. U., Stuchi, N. M. M., Biselli-Chicote, P. M., Henrique, T., Neto, J. A. P., Neto, D. D.-S., Girol, A. P., Pavarino, É. C., & Goloni‐Bertollo, E. M. (2020) · Genes · doi:10.3390/genes11090954 · Cited by 28
“NRF2 regulates the expression of antioxidant proteins in response to oxidative stress in various tissues [9].”
BackgroundhTERT Promotes CRC Proliferation and Migration by Recruiting YBX1 to Increase NRF2 Expression
Gong, C., Yang, H., Wang, S., Liu, J., Li, Z., Hu, Y., Chen, Y., Huang, Y., Luo, Q., Wu, Y., et al. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.658101 · Cited by 32
“Under normal physiological conditions, NRF2 in the cytoplasm is degraded by cullin 3 (CUL3), which is a protein in the KEAP1 complex[14].”
BackgroundEmami, M. H., Sereshki, N., Malakoutikhah, Z., Dehkordi, S. A. E., Fahim, A., Mohammadzadeh, S., & Maghool, F. (2022) · Comparative Biochemistry and Physiology Part C Toxicology & Pharmacology · doi:10.1016/j.cbpc.2022.109266 · Cited by 34
Oncogenic Pathways in Neurodegenerative Diseases
Varela, L., & García-Rendueles, M. E. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23063223 · Cited by 31
“Under upstream signals, such as oxidative stress, Nrf2 dissociates from Keap1, translocates to the nucleus, complexes with ARE and other transcription factors, and induces the transcription of detoxification, antioxidant, metabolism, or proliferative genes [82,83].”
BackgroundHoang, D. H., Buettner, R., Valerio, M., Ghoda, L. Y., Zhang, B., Kuo, Y., Rosen, S. T., Burnett, J., Marcucci, G., Pullarkat, V. A., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23126568 · Cited by 30
“It is still controversial whether activation or inhibition of the Nrf2 antioxidant pathway is beneficial for cancer therapy [51] and likely also depends on the cancer cell type.”
BackgroundJin, C., Molagoda, I. M. N., Karunarathne, W. A. H. M., Kang, S.-H., Park, C., Kim, G., & Choi, Y. H. (2018) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2018.05.022 · Cited by 32
Zhang, B., Wu, J., Cai, Y., Luo, M., Wang, B., & Gu, Y. (2019) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmz015 · Cited by 33
“Constitutive activation of NRF2-ARE protects cancerous cells from oxidative stress [27].”
BackgroundRegulation of stress signaling pathways by nitro-fatty acids
Deen, A. J., Sihvola, V., Härkönen, J., Patinen, T., Adinolfi, S., & Levonen, A. (2018) · Nitric Oxide · doi:10.1016/j.niox.2018.03.012 · Cited by 30
Nrf2‐modulation by seleno‐hormetic agents and its potential for radiation protection
Bartolini, D., Tew, K. D., Marinelli, R., Galli, F., & Wang, G. Y. (2019) · BioFactors · doi:10.1002/biof.1578 · Cited by 30
“Activation of Nrf2 was thought to be a major mechanism of action for many chemoprevention agents in preventing tumorigenesis through inhibition of ROS-mediated DNA.(56,59) Moreover, it has been shown that treatment with 2-trifluoromethyl-20methoxychalone, an oral active Nrf2 inducer, ameliorated total body irradiation…”
BackgroundmiRNA Regulation of Glutathione Homeostasis in Cancer Initiation, Progression and Therapy Resistance
Marengo, B., Pulliero, A., Izzotti, A., & Domenicotti, C. (2019) · MicroRNA · doi:10.2174/2211536609666191218103220 · Cited by 35
Endo, S., Kawai, M., Hoshi, M., Segawa, J., Fujita, M., Matsukawa, T., Fujimoto, N., Matsunaga, T., & Ikari, A. (2021) · The Journal of Biochemistry · doi:10.1093/jb/mvab025 · Cited by 27
Patel, U. N., Patel, U. D., Khadayata, A. V., Vaja, R. K., Modi, C. M., & Patel, H. B. (2022) · Environmental Science and Pollution Research · doi:10.1007/s11356-022-18988-4 · Cited by 28
“Inactive Nrf2 can bind to Kelch-likeECH-associated protein 1 (Keap1), a Nrf2 inhibitor, causing transcriptional activity to be changed (Sporn and Liby 2012).”
BackgroundThe roles of E3 ligases in Hepatocellular carcinoma.
Yu, Z., Li, H., Zhu, J., Wang, H., & Jin, X. (2022) · PubMed · Cited by 31
Drug metabolism and clearance system in tumor cells of patients with multiple myeloma
Hassen, W., Kassambara, A., Reme, T. X., Sahota, S. S., Seckinger, A., Vincent, L., Cartron, G., Moreaux, J., Hose, D., & Klein, B. (2014) · Oncotarget · doi:10.18632/oncotarget.3237 · Cited by 31
Son, Y., Pratheeshkumar, P., Wang, Y., Kim, D., Zhang, Z., & Shi, X. (2017) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2017.04.016 · Cited by 27
“Previous studies showed that Nrf2 is able to bind to the ARE in the promoter region of the Bcl-2 gene, leading to an up-regulation of Bcl-2 and decrease in apoptosis (Calvert et al., 2009; Lau et al., 2013; Mukherjee et al., 2013; Ohta et al., 2008; Sporn and Liby, 2012; Tong et al., 2006).”
BackgroundInfluentialBedini, A., Fraternale, A., Crinelli, R., Mari, M., Bartolucci, S., Chiarantini, L., & Spadoni, G. (2018) · Chemical Research in Toxicology · doi:10.1021/acs.chemrestox.8b00216 · Cited by 29
Li, P., Lin, N., Guo, M., Huang, H., Yu, T., & Zhang, L. (2019) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2019.08.095 · Cited by 28
Gan, L., Wang, W., Jiang, J., Tian, K., Liu, W., & Cao, Z. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1429836 · Cited by 37
“Nrf2 inhibits malignant transformation by protecting both healthy and malignant cells from damage caused by free radicals; nevertheless, it provides therapy resistance once cancer has established itself (83).”
BackgroundThe significant others of aurora kinase a in cancer: combination is the key
Nikhil, K., & Shah, K. (2024) · Biomarker Research · doi:10.1186/s40364-024-00651-4 · Cited by 34
“Under physiological and premalignant conditions, Nrf2 activation is cancer preventive, but in malignant situations, Nrf2 activation promotes chemoresistance and tumorigenesis [128].”
BackgroundMosca, S., Cardinali, G., Flori, E., Briganti, S., Bottillo, I., Mileo, A. M., & Maresca, V. (2020) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12910 · Cited by 24
“The PI3K/pAKT pathway is involved in regulating antioxidant responses (De Nicola et al., 2011; Koundouros & Poulogiannis, 2018; Sporn & Liby, 2012); thus, we decided to evaluate the redox state following the different treatments.”
BackgroundElsherbiny, N. M., Eisa, N. H., El‐Sherbiny, M., & Said, E. (2020) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2020.103494 · Cited by 28
Monnerat, J. A. D. S., de Souza, P. R., Cardoso, L. M. D. F., Mattos, J. D., Rocha, G. D. S., & Medeiros, R. F. (2020) · European Journal of Nutrition · doi:10.1007/s00394-020-02410-1 · Cited by 29
Meng, X., Zhang, L., Han, B., & Zheng, Z. (2021) · Environmental Toxicology · doi:10.1002/tox.23340 · Cited by 26
“Nuclear factor erythroid-derived 2-related factor 2 (Nrf2) is a well-known cytoprotective protein that enables cell survival under various stress conditions.(15) Nrf2 is a transcription factor”
BackgroundThe nexus between redox state and intermediary metabolism
Zoccarato, A., Nabeebaccus, A., Oexner, R. R., Santos, C. X. C., & Shah, A. M. (2021) · FEBS Journal · doi:10.1111/febs.16191 · Cited by 31
Reprogramming of iron metabolism confers ferroptosis resistance in ECM-detached cells
He, J., Abikoye, A. M., McLaughlin, B. P., Middleton, R. S., Sheldon, R. D., Jones, R. G., & Schafer, Z. T. (2023) · iScience · doi:10.1016/j.isci.2023.106827 · Cited by 27
“Both FTH1 and FTL are known targets of the NRF2 transcription factor,(52,53) which is typically activated to neutralize excess oxidative stress.(54,55) Given that ECM-detached cells are often exposed to elevated oxidative stress,(4,9,56) we investigated the levels of NRF2 when cells are grown in ECM-detached condition…”
Wang, Y., DaCosta, C. M., Wang, W., Zhou, Z., Liu, M., & Bao, Y. (2015) · Nutrition Research · doi:10.1016/j.nutres.2015.05.011 · Cited by 31
“[25] Sporn MB, Liby KT.”
BackgroundUncovering metabolism in rhabdomyosarcoma
Monti, E., & Fanzani, A. (2016) · Cell Cycle · doi:10.1080/15384101.2015.1071746 · Cited by 29
“Finally, it should be mentioned that the expression levels of GSH reductase, TXN reductase and catalase are all under direct transcriptional control of the nuclear factor erythroid 2-related factor (NRF2) [112], which is expressed in a broad spectrum of sarcomas, including RMS [113].”
Genetic polymorphism in the NRF2 gene as a prognosis marker for cancer chemotherapy
Ishikawa, T. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00383 · Cited by 32
Dimethyl fumarate: a Janus-faced substance?
Kees, F. (2013) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2013.804912 · Cited by 29
“Nrf-2 has been assumed to be potentially involved in the development of human carcinomas [60].”
BackgroundReduced mRNA expression levels of NFE2L2 are associated with poor outcome in breast cancer patients
Wolf, B., Goebel, G., Hackl, H., & Fiegl, H. (2016) · BMC Cancer · doi:10.1186/s12885-016-2840-x · Cited by 27
“This dual role of NFE2L2 is extensively discussed and there is common agreement that the arguments of both sides of this paradox are of value and about the great importance of the context [30, 33, 34].”
Autophagy involved in the activation of the Nrf2-antioxidant system in testes of heat-exposed mice
Li, Z., Li, Y., Zhou, X. E., Dai, P., & Li, C. (2017) · Journal of Thermal Biology · doi:10.1016/j.jtherbio.2017.11.006 · Cited by 27
Noh, Y., Jeon, S., & Shin, S. (2018) · International Journal of Cancer · doi:10.1002/ijc.31870 · Cited by 29
NRF2/KEAP1 and Wnt/β‐catenin in the multistep process of liver carcinogenesis in humans and rats
Nault, J., Rebouissou, S., & Zucman‐Rossi, J. (2015) · Hepatology · doi:10.1002/hep.27828 · Cited by 28
“NRF2 and KEAP1 are the key players of the oxidative stress pathway that trigger an antioxidant response program when cells are exposed to reactive oxygen species (ROS).(4) In an inactivate state, NFR2 (coded by NFE2L2) is a transcription factor retained in the cytoplasm through its binding by KEAP1 and cullin 3 (CUL3;…”
BackgroundNRF2 inhibitors: Recent progress, future design and therapeutic potential
Lv, B., Xing, S., Wang, Z., Zhang, A., Wang, Q., Bian, Y., Pei, Y., Sun, H., & Chen, Y. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116822 · Cited by 33
Zhu, Z., Chen, X., Sun, J., Li, Q., Lian, X., Li, S., Wang, Y., & Tian, L. (2018) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2018.10.438 · Cited by 25
The role of ferroptosis in digestive system cancer (Review)
Song, Y., Hu, Y., Lin, R., Jiang, K., & Wang, B. (2019) · Oncology Letters · doi:10.3892/ol.2019.10568 · Cited by 37
Induction of ferroptosis in head and neck cancer: A novel bridgehead for fighting cancer resilience
Lee, J., & Roh, J. (2022) · Cancer Letters · doi:10.1016/j.canlet.2022.215854 · Cited by 28
Interaction of saffron and its constituents with Nrf2 signaling pathway: A review.
Khoshandam, A., Razavi, B. M., & Hosseinzadeh, H. (2022) · PubMed Central · doi:10.22038/ijbms.2022.61986.13719 · Cited by 24
“Hence, the complex of Nrf2keap1 is disrupted and Nrf2 accumulates in the cytoplasm with high concentrations leading to its translocation to the nucleus and triggering several cytoprotective events such as molecular chaperones, anti-oxidant and phase II detoxification enzymes, and anti-inflammatory (48, 49).”
BackgroundZhong, M., He, J., Zhang, B., Liu, Q., & Fang, J. (2022) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2022.12.091 · Cited by 26
Sun, X., Dong, M., Li, J., Sun, Y., Gao, Y., Wang, Y., Du, L., Liu, Y., Ji, K., He, N., et al. (2024) · Theranostics · doi:10.7150/thno.88899 · Cited by 32
“NRF2 activation may play a role in avoiding precancerous occurrence in the early stage of tumorigenesis [46,47].”
BackgroundCai, M., Chen, M., Ma, P., Wu, J., Lu, H., Zhang, S., Liu, J., Zhao, X., Zhuang, G., Yu, Z., et al. (2018) · International Journal of Cancer · doi:10.1002/ijc.31975 · Cited by 27
Glucose negatively affects Nrf2/SKN-1-mediated innate immunity in C. elegans
Li, L., Chen, Y., Chenzhao, C., Fu, S., Xu, Q., & Zhao, J. (2018) · Aging · doi:10.18632/aging.101610 · Cited by 23
Luk, S. T.-C., Ng, K. Y., Zhou, L., Tong, M., Wong, T. L., Yu, H., Lo, C., Man, K., Guan, X., Lee, T. K., et al. (2019) · Hepatology · doi:10.1002/hep.31020 · Cited by 27
“Many of these targets are antioxidant-producing genes, and thus NRF2 is able to regulate the production of ROS.(26,36) p38 MAPK is also known to influence F-actin reorganization through the resultant phosphorylation of heat shock FIg.”
BackgroundWang, J., Zhang, W., Lv, C., Wang, Y., Ma, B., Zhang, H., Fan, Z., Li, M., & Li, X. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107918 · Cited by 27
Kong, Q., Deng, H., Li, C., Wang, X., Shimoda, Y., Tao, S., Kato, K., Zhang, J., Yamanaka, K., & An, Y. (2020) · The Science of The Total Environment · doi:10.1016/j.scitotenv.2020.143840 · Cited by 26
Targeting Nrf2 in healthy and malignant ovarian epithelial cells: Protection versus promotion
van der Wijst, M. G. P., Huisman, C., Mposhi, A., Roelfes, G., & Rots, M. G. (2015) · Molecular Oncology · doi:10.1016/j.molonc.2015.03.003 · Cited by 29
“However, caution should be taken as the function of Nrf2 is context dependent (66).”
BackgroundJin, X., Gong, L., Peng, Y., Li, L., & Liu, G. (2021) · Aging · doi:10.18632/aging.202137 · Cited by 24
Nrf2/Keap1/ARE regulation by plant secondary metabolites: a new horizon in brain tumor management
Dewanjee, S., Bhattacharya, H., Bhattacharyya, C., Chakraborty, P., Fleishman, J. S., Alexiou, A. T., Papadakis, M., & Jha, S. K. (2024) · Cell Communication and Signaling · doi:10.1186/s12964-024-01878-2 · Cited by 30
“On the other hand, prevention and/ or inhibition of Nrf2 pathway by high dose of hormetic Nrf2 modulators would lead to cell death by promoting ROS and doing away with chemoresistance in malignant cells [43].”
BackgroundJiang, Y., Khoury, E. E., Pezacki, A. T., Qian, N., Oi, M., Torrente, L., Miller, S. G., Ralle, M., DeNicola, G. M., Min, W., et al. (2024) · Journal of the American Chemical Society · doi:10.1021/jacs.4c06296 · Cited by 28
Metadata
- Authors
- Sporn, M. B., & Liby, K. T.
- Affiliations
- Dartmouth College (US)
- Corresponding author
- Sporn, Michael B.
- Liby, Karen T.
- ORCID
- Liby, Karen T.
- Venue
- Nature Reviews Cancer
- Published
- 2012-07-19
- Volume
- 12
- Issue
- 8
- Pages
- 564-571
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- PMC
- PMC3836441
- OpenAlex
- W2030749349
- Cited by
- 1,067
- References
- 120
- Citations by year
- 2026: 36 · 2025: 48 · 2024: 70 · 2023: 72 · 2022: 88 · 2021: 90 · 2020: 97 · 2019: 93 · 2018: 112 · 2017: 88 · 2016: 93 · 2015: 62 · 2014: 57 · 2013: 50 · 2012: 11
- FWCI
- 5.31
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (R01CA078814, P30CA023108)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics, phytochemicals, and oxidative stress
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Bioactive Compounds and Antitumor Agents
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Glutathione Transferases and Polymorphisms
- Keywords
- Nrf2, chemoprevention, carcinogenesis, chemoresistance, transcription factor activation
- MeSH terms
- Animals, Cell Transformation, Neoplastic, Humans, Neoplasms, Anticarcinogenic Agents, Tumor Suppressor Proteins, NF-E2-Related Factor 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.